<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18276">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01858610</url>
  </required_header>
  <id_info>
    <org_study_id>PPT4</org_study_id>
    <nct_id>NCT01858610</nct_id>
  </id_info>
  <brief_title>Drug Interaction Between Irbesartan and Hydrochlorothiazide</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <authority>Egypt: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to investigate any potential reaction between irbesartan and
      hydrochlorothiazide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Blood pressure (systolic/diastolic)</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 5 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetic parameter such as the Cmax of irbesartan and hydrochlorothiazide</measure>
    <time_frame>After collection of all blood samples, an expected average of 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 5 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetic parameter such as the AUC of irbesartan and hydrochlorothiazide</measure>
    <time_frame>After collection of all blood samples, an expected average of 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Irbesartan alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Irbesartan 300 mg alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide 25 mg alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hydrochlorothiazide 25 mg alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irbesartan 300 mg + Hydrochlorothiazide 25 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Irbesartan 300 mg + Hydrochlorothiazide 25 fixed dose combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbeasartan/hydrochlorothiazide</intervention_name>
    <arm_group_label>Irbesartan 300 mg + Hydrochlorothiazide 25 mg</arm_group_label>
    <other_name>Fixed dose combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <arm_group_label>Irbesartan alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <arm_group_label>Hydrochlorothiazide 25 mg alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        At least 18 years old and not more than 45 healthy normotensive male volunteers Who had
        passed all the screening parameters

        Exclusion Criteria:

        A clinically significant abnormal physical exam, medical history, or laboratory studies If
        they showed a sitting SBP of &gt;140 or &lt;100 mmHg, DBP &gt; 90 or &lt;60mm Hg, or a pulse rate of &gt;
        95 or &lt; 50 beats/min at screening The use of any prescription drug within the previous
        month or use of any over-the-counter medication within the past 14 days A history of blood
        dyscrasias A history of alcohol or drug abuse within the past year Donation of blood
        during the 8 weeks prior to the study or plans to donate blood during or within 8 weeks of
        completing the study Unable to tolerate vein puncture and multiple blood samplings Any
        surgical/medical condition that might alter drug absorption, distribution, metabolism, or
        excretion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmaceutics Department, Faculty of Pharmacy, Damanhour University</name>
      <address>
        <city>Damanhour</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 24, 2013</lastchanged_date>
  <firstreceived_date>May 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Sally Helmy, PhD, CPHQ</investigator_full_name>
    <investigator_title>Lecturer of Pharmaceutics, Faculty of Pharmacy</investigator_title>
  </responsible_party>
  <keyword>Fixed dose combination</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Irbesartan</keyword>
  <keyword>Hydrochlorothiazide</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Normotensive Participants</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
